Influenza vaccination in subjects with α1-antitrypsin deficiency

Michael A Campos, Saleh Alazemi, Guoyan Zhang, Robert A. Sandhaus, Adam Wanner

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Influenza vaccination is recommended for all subjects with COPD, including α1-antitrypsin deficiency (AATD), but immunization practices are below US national goals. Influenza vaccination practices and their relation to respiratory outcomes in AATD are unknown. Methods: Nine hundred thirty-nine subjects with AATD were followed up prospectively by monthly telephone interviews during the 2003 to 2004 influenza season. Vaccination status, exacerbation rates, and health-care utilization were documented. Residence zip codes were used to group subjects as living in high or low influenza-like illness (ILI) prevalence areas according to published Centers for Disease Control and Prevention data for the same influenza season. Results: Overall, 81.6% of subjects received influenza vaccination, with no differences noted by gender, age (median age 52 years), Global Initiative for Chronic Obstructive Lung Disease stage, or ILI prevalence area. No significant differences were noted in the overall acute exacerbation rates using two different criteria between vaccinated and unvaccinated subjects (mean, 1.5 ± 1 exacerbations per subject). Similarly, no differences were noted in either the severity of exacerbations or the monthly exacerbation rates between the two groups. Unvaccinated subjects had more unscheduled physician visits than vaccinated subjects, but there were no significant differences in scheduled visits, emergency department visits, or hospitalizations between the two groups. Older age (> 60 years) or residence in a high ILI prevalence area had no effect on outcomes. Conclusion: Subjects with AATD in the United States receive adequate influenza vaccination regardless of age. However, we did not observe a significant impact of the vaccination on disease exacerbations and other respiratory outcomes during the 2003 to 2004 influenza season.

Original languageEnglish
Pages (from-to)49-55
Number of pages7
JournalChest
Volume133
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Human Influenza
Vaccination
Chronic Obstructive Pulmonary Disease
Patient Acceptance of Health Care
Centers for Disease Control and Prevention (U.S.)
Disease Progression
Hospital Emergency Service
Immunization
Hospitalization
Interviews
Physicians

Keywords

  • α-antitrypsin deficiency
  • Influenza vaccines
  • Outcome assessment (health care)
  • Pulmonary disease, chronic obstructive

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Influenza vaccination in subjects with α1-antitrypsin deficiency. / Campos, Michael A; Alazemi, Saleh; Zhang, Guoyan; Sandhaus, Robert A.; Wanner, Adam.

In: Chest, Vol. 133, No. 1, 01.01.2008, p. 49-55.

Research output: Contribution to journalArticle

Campos, Michael A ; Alazemi, Saleh ; Zhang, Guoyan ; Sandhaus, Robert A. ; Wanner, Adam. / Influenza vaccination in subjects with α1-antitrypsin deficiency. In: Chest. 2008 ; Vol. 133, No. 1. pp. 49-55.
@article{486165eae7a14b4088b890a8c20d9883,
title = "Influenza vaccination in subjects with α1-antitrypsin deficiency",
abstract = "Background: Influenza vaccination is recommended for all subjects with COPD, including α1-antitrypsin deficiency (AATD), but immunization practices are below US national goals. Influenza vaccination practices and their relation to respiratory outcomes in AATD are unknown. Methods: Nine hundred thirty-nine subjects with AATD were followed up prospectively by monthly telephone interviews during the 2003 to 2004 influenza season. Vaccination status, exacerbation rates, and health-care utilization were documented. Residence zip codes were used to group subjects as living in high or low influenza-like illness (ILI) prevalence areas according to published Centers for Disease Control and Prevention data for the same influenza season. Results: Overall, 81.6{\%} of subjects received influenza vaccination, with no differences noted by gender, age (median age 52 years), Global Initiative for Chronic Obstructive Lung Disease stage, or ILI prevalence area. No significant differences were noted in the overall acute exacerbation rates using two different criteria between vaccinated and unvaccinated subjects (mean, 1.5 ± 1 exacerbations per subject). Similarly, no differences were noted in either the severity of exacerbations or the monthly exacerbation rates between the two groups. Unvaccinated subjects had more unscheduled physician visits than vaccinated subjects, but there were no significant differences in scheduled visits, emergency department visits, or hospitalizations between the two groups. Older age (> 60 years) or residence in a high ILI prevalence area had no effect on outcomes. Conclusion: Subjects with AATD in the United States receive adequate influenza vaccination regardless of age. However, we did not observe a significant impact of the vaccination on disease exacerbations and other respiratory outcomes during the 2003 to 2004 influenza season.",
keywords = "α-antitrypsin deficiency, Influenza vaccines, Outcome assessment (health care), Pulmonary disease, chronic obstructive",
author = "Campos, {Michael A} and Saleh Alazemi and Guoyan Zhang and Sandhaus, {Robert A.} and Adam Wanner",
year = "2008",
month = "1",
day = "1",
doi = "10.1378/chest.07-1482",
language = "English",
volume = "133",
pages = "49--55",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1",

}

TY - JOUR

T1 - Influenza vaccination in subjects with α1-antitrypsin deficiency

AU - Campos, Michael A

AU - Alazemi, Saleh

AU - Zhang, Guoyan

AU - Sandhaus, Robert A.

AU - Wanner, Adam

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Background: Influenza vaccination is recommended for all subjects with COPD, including α1-antitrypsin deficiency (AATD), but immunization practices are below US national goals. Influenza vaccination practices and their relation to respiratory outcomes in AATD are unknown. Methods: Nine hundred thirty-nine subjects with AATD were followed up prospectively by monthly telephone interviews during the 2003 to 2004 influenza season. Vaccination status, exacerbation rates, and health-care utilization were documented. Residence zip codes were used to group subjects as living in high or low influenza-like illness (ILI) prevalence areas according to published Centers for Disease Control and Prevention data for the same influenza season. Results: Overall, 81.6% of subjects received influenza vaccination, with no differences noted by gender, age (median age 52 years), Global Initiative for Chronic Obstructive Lung Disease stage, or ILI prevalence area. No significant differences were noted in the overall acute exacerbation rates using two different criteria between vaccinated and unvaccinated subjects (mean, 1.5 ± 1 exacerbations per subject). Similarly, no differences were noted in either the severity of exacerbations or the monthly exacerbation rates between the two groups. Unvaccinated subjects had more unscheduled physician visits than vaccinated subjects, but there were no significant differences in scheduled visits, emergency department visits, or hospitalizations between the two groups. Older age (> 60 years) or residence in a high ILI prevalence area had no effect on outcomes. Conclusion: Subjects with AATD in the United States receive adequate influenza vaccination regardless of age. However, we did not observe a significant impact of the vaccination on disease exacerbations and other respiratory outcomes during the 2003 to 2004 influenza season.

AB - Background: Influenza vaccination is recommended for all subjects with COPD, including α1-antitrypsin deficiency (AATD), but immunization practices are below US national goals. Influenza vaccination practices and their relation to respiratory outcomes in AATD are unknown. Methods: Nine hundred thirty-nine subjects with AATD were followed up prospectively by monthly telephone interviews during the 2003 to 2004 influenza season. Vaccination status, exacerbation rates, and health-care utilization were documented. Residence zip codes were used to group subjects as living in high or low influenza-like illness (ILI) prevalence areas according to published Centers for Disease Control and Prevention data for the same influenza season. Results: Overall, 81.6% of subjects received influenza vaccination, with no differences noted by gender, age (median age 52 years), Global Initiative for Chronic Obstructive Lung Disease stage, or ILI prevalence area. No significant differences were noted in the overall acute exacerbation rates using two different criteria between vaccinated and unvaccinated subjects (mean, 1.5 ± 1 exacerbations per subject). Similarly, no differences were noted in either the severity of exacerbations or the monthly exacerbation rates between the two groups. Unvaccinated subjects had more unscheduled physician visits than vaccinated subjects, but there were no significant differences in scheduled visits, emergency department visits, or hospitalizations between the two groups. Older age (> 60 years) or residence in a high ILI prevalence area had no effect on outcomes. Conclusion: Subjects with AATD in the United States receive adequate influenza vaccination regardless of age. However, we did not observe a significant impact of the vaccination on disease exacerbations and other respiratory outcomes during the 2003 to 2004 influenza season.

KW - α-antitrypsin deficiency

KW - Influenza vaccines

KW - Outcome assessment (health care)

KW - Pulmonary disease, chronic obstructive

UR - http://www.scopus.com/inward/record.url?scp=38349053915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349053915&partnerID=8YFLogxK

U2 - 10.1378/chest.07-1482

DO - 10.1378/chest.07-1482

M3 - Article

C2 - 17908701

AN - SCOPUS:38349053915

VL - 133

SP - 49

EP - 55

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -